3 Results for "

MCF10A normal breast epithelial cells

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "MCF10A normal breast epithelial cells" in MCE Product Catalog:

Cat. No.: HY-W010713
CAS No.: 2669-65-0
Synonyms: Fimaporfin free base
Target:  

Photosensitizer

Research Areas:  

Cancer

Meso-tetraphenylchlorin (TPCS2a) is a photosensitizer with poor water solubility, which limits its use in the blood circulation. However, TPCS2a@NPs nanoparticles can be prepared based on polylactic-co-polyethylene glycol acid (PLGA) polymer core loaded with TPCS2. Such nanoparticles can be coated with mesenchymal stem cell-derived plasma membranes (mMSCs) to form mMSC-TPCS2a@NPs, which prolongs blood circulation time and improves tumor targeting ability. Compared with uncoated TPCS2a@NPs, mMSC-TPCS2a@NPs can reduce macrophage uptake by 54% to 70% under different conditions. Both nanoparticle forms are effectively accumulated in MCF7 and MDA-MB-231 breast cancer cells, while uptake in normal breast epithelial cells MCF10A is significantly lower .
loading...
    loading...
Cat. No.: HY-172937
CAS No.: 3070968-56-5
ERα degrader 13 is an orally active, methylene blue-Raloxifene (HY-13738) conjugated photoactivatable ERα degrader with a Kd value of 27.1 nM. Upon irradiation at 660 nm, ERα degrader 13 generates ROS and heat near the ligand-binding domain of ERα, triggering oxidation, residue unfolding, and ERα degradation via the ubiquitin-proteasome system. ERα degrader 13 inhibits cancer cell proliferation and induces tumor regression in breast cancer xenograft models. ERα degrader 13 can be used in breast cancer-related research .
loading...
    loading...
Cat. No.: HY-183294
CAS No.: 2834106-56-6
GPX4-IN-24 is an orally active glutathione peroxidase 4 (GPX4) inhibitor with a human IC50 of 10.90 μM, human Kd of 10.04 μM. GPX4-IN-24 suppresses GPX4 enzymatic activity, disrupts redox homeostasis, drives lipid peroxidation, promotes lipid peroxidation, and induces ferroptosis. GPX4-IN-24 can be used for the research of triple-negative breast cancer .
loading...
    loading...